Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants (R-S-)
This randomised, triple-blind, placebo-controlled Phase I crossover trial (n=24) will compare the acute effects of two enantiomers of MDMA—R-MDMA (300 mg) and S-MDMA (100 mg)—in healthy adult participants.
Details
Randomised, triple-blind, placebo-controlled 3-period crossover in healthy volunteers to compare acute subjective and physiological effects of single oral doses of R-MDMA (300 mg) and S-MDMA (100 mg) against placebo.
Primary aim is basic science characterisation of enantiomer-specific pharmacology and subjective effects; outcomes include vital signs, adverse events and standard psychometric instruments.
Each participant receives three single-dose sessions (R-MDMA, S-MDMA, placebo) with washout between periods; estimated enrollment 24 at University Hospital Basel.